1. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
   Kazuhisa Yamaguchi et al, 2015, BMC Cancer CrossRef
2. Incorporation of biomarkers in phase II studies of recurrent glioblastoma
   Toni Rose Jue et al, 2015, Tumor Biology CrossRef
3. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
   Richard M. Goldberg et al, 2018, ESMO Open CrossRef
4. Bevacizumab
   , 2019, Reactions Weekly CrossRef
5. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma
   Marc Peeters et al, 2018, ESMO Open CrossRef
6. OPTIMAL SEQUENCES AND COMBINATION OF CHEMOTHERAPY AND MONOCLONAL ANTIBODIES IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
   M. Yu. Fedyanin et al, 2018, Malignant tumours CrossRef
7. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
   Jennifer Hazel Elizabeth Baker et al, 2018, Clinical & Experimental Metastasis CrossRef
8. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
   Alessandro Parisi et al, 2020, Cancers CrossRef
9. Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
   Hiroya Taniguchi et al, 2018, Neoplasia CrossRef